Sept 2 (Reuters) - Cynapsus Therapeutics Inc CTH.TO :
* Enrolls first patient in pivotal phase 3 safety study of apl-130277 for the
treatment of off episodes in patients with parkinson's disease
* Says cth-300, a pivotal phase 3 efficacy study, is also ongoing with data
expected from both trials in 2016
* Source text for Eikon ID:nGNXVEIZJa
* Further company coverage CTH.TO